Erben, R. G. Physiological actions of fibroblast growth factor-23. Front. Endocrinol. 9, 267 (2018).
Agoro, R., Ni, P., Noonan, M. L. & White, K. E. Osteocytic FGF23 and its kidney function. Front. Endocrinol. 11, 592 (2020).
Gattineni, J. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am. J. Physiol. Renal Physiol. 297, F282 (2009).
Forster, I. C., Hernando, N., Biber, J. & Murer, H. Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med. 34, 386–395 (2013).
Shimada, T. et al. Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am. J. Physiol. Renal Physiol. 289, F1088–F1095 (2005).
Norman, A. W. et al. 1.25(OH)2-vitamin D3, a steroid hormone that produces biologic effects via both genomic and nongenomic pathways. J. Steroid Biochem. Mol. Biol. 41, 231–240 (1992).
Urakawa, I. et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444, 770–774 (2006).
Kuro-o, M. et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 390, 45–51 (1997).
Sitara, D. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23, 421–432 (2004).
Razzaque, M. S. & Lanske, B. Hypervitaminosis D and premature aging: Lessons learned from Fgf23 and Klotho mutant mice. Trends Mol. Med. 12, 298–305 (2006).
Leifheit-Nestler, M. et al. Induction of cardiac FGF23/FGFR4 expression is associated with left ventricular hypertrophy in patients with chronic kidney disease. Nephrol. Dial. Transplant. 31, 1088–1099 (2016).
Singh, S. et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int. 90, 985–996 (2016).
Spichtig, D. et al. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease. Kidney Int. 85, 1340–1350 (2014).
van Venrooij, N. A. et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol. Dial. Transplant. 29, 1525–1532 (2014).
Andrukhova, O., Slavic, S., Odörfer, K. I. & Erben, R. G. Experimental myocardial infarction upregulates circulating fibroblast growth factor-23. J. Bone Miner. Res. 30, 1831–1839 (2015).
Bienaimé, F. et al. Hepatic production of fibroblast growth factor 23 in autosomal dominant polycystic kidney disease. J. Clin. Endocrinol. Metab. 103, 2319–2328 (2018).
Zanchi, C. et al. Renal expression of FGF23 in progressive renal disease of diabetes and the effect of ACE inhibitor. PLOS ONE 8, e70775 (2013).
Leifheit-Nestler, M. & Haffner, D. Paracrine effects of FGF23 on the heart. Front. Endocrinol. 9, 278 (2018).
Si, Y. et al. FGF23, a novel muscle biomarker detected in the early stages of ALS. Sci. Rep. 11, 12062 (2021).
Di Giuseppe, R. et al. Plasma fibroblast growth factor 23 and risk of cardiovascular disease: Results from the EPIC-Germany case-cohort study. Eur. J. Epidemiol. 30, 131–141 (2015).
Wahl, P. & Wolf, M. in Endocrine FGFs and Klothos (eds Kuro-o, M.) 107–125 (Springer US, 2012).
Fliser, D. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The mild to moderate kidney disease (MMKD) study. JASN 18, 2600–2608 (2007).
Cornelissen, A. et al. Intact fibroblast growth factor 23 levels and outcome prediction in patients with acute heart failure. Sci. Rep. 11, 15507 (2021).
Faul, C. et al. FGF23 induces left ventricular hypertrophy. J. Clin. Investig. 121, 4393–4408 (2011).
Walker, E. C. et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. J. Clin. Investig. 120, 582–592 (2010).
Chen, C.-Y. et al. CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways. PLOS ONE 9, e106632 (2014).
Heinrich, P. C., Behrmann, I., Müller-Newen, G., Schaper, F. & Graeve, L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem. J. 334(Pt 2), 297–314 (1998).
Quarles, L. D. Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat. Rev. Endocrinol. 8, 276–286 (2012).
David, V. et al. Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production. Kidney Int. 89, 135–146 (2016).
Durlacher-Betzer, K. et al. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int. 94, 315–325 (2018).
Sims, N. A. & Walsh, N. C. GP130 cytokines and bone remodelling in health and disease. BMB Rep. 43, 513–523 (2010).
Palmqvist, P., Persson, E., Conaway, H. H. & Lerner, U. H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J. Immunol. 169, 3353–3362 (2002).
Zeng, S. et al. Relationship between GFR, intact PTH, oxidized PTH, non-oxidized PTH as well as FGF23 in patients with CKD. FASEB J. 34, 15269–15281 (2020).
Walker, E. C. et al. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo. J. Bone Miner. Res. 27, 902–912 (2012).
Richter, M. et al. The failing heart is a major source of circulating FGF23 via oncostatin M receptor activation. J. Heart Lung Transplant. 34, 1211–1214 (2015).
Alber, J. & Föller, M. Lactic acid induces fibroblast growth factor 23 (FGF23) production in UMR106 osteoblast-like cells. Mol. Cell. Biochem. 477, 363–370 (2022).
Liu, S. et al. Pathogenic role of Fgf23 in Dmp1-null mice. Am. J. Physiol. Endocrinol. Metab. 295, E254–E261 (2008).
Liu, S. et al. Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J. Biol. Chem. 278, 37419–37426 (2003).
Clinkenbeard, E. L. et al. Erythropoietin stimulates murine and human fibroblast growth factor-23, revealing novel roles for bone and bone marrow. Haematologica 102, e427–e430 (2017).
Ito, M. et al. Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am. J. Physiol. Endocrinol. Metab. 288, E1101–E1109 (2005).
Lavi-Moshayoff, V., Wasserman, G., Meir, T., Silver, J. & Naveh-Many, T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: A bone parathyroid feedback loop. Am. J. Physiol. Renal Physiol. 299, F882–F889 (2010).
López, I. et al. Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney Int. 80, 475–482 (2011).
Mosley, B. et al. Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J. Biol. Chem. 271, 32635–32643 (1996).
Fossey, S. L., Bear, M. D., Kisseberth, W. C., Pennell, M. & London, C. A. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines. BMC Cancer 11, 125 (2011).
Ehlting, C. et al. Oncostatin M regulates SOCS3 mRNA stability via the MEK-ERK1/2-pathway independent of p38(MAPK)/MK2. Cell. Signal. 27, 555–567 (2015).
Rose-John, S. Interleukin-6 family cytokines. Cold Spring Harb. Perspect. Biol. 10, 028415 (2018).
Metcalfe, R. D., Putoczki, T. L. & Griffin, M. D. W. Structural understanding of interleukin 6 family cytokine signalling and targeted therapies: Focus on interleukin 11. Front. Immunol. 11, 1424 (2020).
Isakova, T. et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 79, 1370–1378 (2011).
Egli-Spichtig, D. et al. Tumor necrosis factor stimulates fibroblast growth factor 23 levels in chronic kidney disease and non-renal inflammation. Kidney Int. 96, 890–905 (2019).
West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).
Masjedi, A. et al. Oncostatin M: A mysterious cytokine in cancers. Int. Immunopharmacol. 90, 107158 (2021).
El-Hodhod, M.A.-A., Hamdy, A. M., Abbas, A. A., Moftah, S. G. & Ramadan, A. A. M. Fibroblast growth factor 23 contributes to diminished bone mineral density in childhood inflammatory bowel disease. BMC Gastroenterol. 12, 44 (2012).
Ewendt, F., Feger, M. & Föller, M. Role of fibroblast growth factor 23 (FGF23) and αKlotho in cancer. Front. Cell Dev. Biol. 8, 601006 (2020).
Luyckx, V. A., Cairo, L. V., Compston, C. A., Phan, W. L. & Mueller, T. F. Oncostatin M pathway plays a major role in the renal acute phase response. Am. J. Physiol. Renal Physiol. 296, F875–F883 (2009).
Elbjeirami, W. M. et al. Early differential expression of oncostatin M in obstructive nephropathy. J. Interferon Cytokine Res. 30, 513–523 (2010).
Sims, N. A. & Quinn, J. M. W. Osteoimmunology: Oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease. BoneKEy Rep. 3, 527 (2014).
Guihard, P. et al. Oncostatin M, an inflammatory cytokine produced by macrophages, supports intramembranous bone healing in a mouse model of tibia injury. Am. J. Pathol. 185, 765–775 (2015).
Damman, K. et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur. Heart J. 35, 455–469 (2014).
Kendrick, J. et al. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J. Am. Soc. Nephrol. 22, 1913–1922 (2011).
Yoshimura, A. et al. Mouse oncostatin M: An immediate early gene induced by multiple cytokines through the JAK-STAT5 pathway. EMBO J. 15, 1055–1063 (1996).
Feger, M. et al. Glucocorticoids dexamethasone and prednisolone suppress fibroblast growth factor 23 (FGF23). J. Mol. Med. (Berl.) 99, 699–711 (2021).